Inhaled 'Smart' particles aim to halt lung scarring
NCT ID NCT07571291
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is developing a new way to treat pulmonary fibrosis, a condition where the lungs become scarred and stiff. The approach uses tiny particles called liposomes, coated with hyaluronic acid, to deliver drugs directly to the cells that cause scarring. The research is being done in the lab and in mice, using cells and tissues from 30 patients, to see if the particles are safe and can target the right cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomes coated with hyaluronic acid (XHALIP)
What this could lead to
If successful, this could lead to a more targeted, inhaled treatment for pulmonary fibrosis with fewer side effects.
What could go wrong
This is a very early, small lab and animal study. It may not translate to humans, and the liposome technology is still experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rheumatology unit IRCCS Policlinico San Matteo Pavia
Pavia, 27100, Italy